AUTO-COVID-VACC

To analyze the available data on neutralizing capacity against the Omicron variant after repeated mRNA vaccinations in patients post autologous hematopoietic stem cell transplant (HSCT) for B- non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

• To analyze the available data on binding antibody response against the Omicron variant after repeated mRNA vaccinations in patients who underwent autologous HSCT.
• To analyze the available data on waning of humoral immune response against the Omicron variant after last mRNA vaccine in successfully vaccinated patients.
• To analyze reactogenicity data collected within this study.

• Patient 42 days (±3) post autologous HSCT for B-cell non-Hodgkin lymphoma or Hodgkin lymphoma.
• Patient is 30 years of age or older at enrollment.
• Patients are eligible for study inclusion with or without confirmed SARS-CoV-2 infection prior to autologous HSCT.
• Patient is treated at an institution that practices the standard-of-care COVID-19 vaccination (Appendix 1).
• Patient has received 3 or more vaccinations with an anti-SARS-CoV-2 mRNA vaccine prior to autologous HSCT.
• Patient planned to be vaccinated against COVID-19 according to the hospital standard (Appendix 1).
• Written informed consent from patient has been obtained prior to any study related procedures (Section 12.3).

• Patient with confirmed SARS-CoV-2 infection between d0 and d42 after autologous HSCT.
• Patient has a positive SARS-CoV-2 antigen test at visit d42.
• Patient has received less than 3 vaccinations with an anti-SARS-CoV-2 mRNA vaccine prior to autologous HSCT.

keine, da nicht-interventionelle Studie